New, Investigational Procedure May Help Treat Patients with Resistant Hypertension
The procedure is called renal denervation, which involves a catheter-based probe that delivers low-level radiofrequency energy through the wall of the blood vessel to the kidney to disrupt the nerves leading into and out of the kidneys. Patients who have hypertension may have hyperactive renal nerves, which increase blood pressure. By deactivating the renal nerves, a significant reduction in blood pressure may be achieved.
“We’re very excited about this technology,” said Dr. Benzuly. “It has the potential to help a large number of patients with uncontrolled blood pressure.”
Research suggests that up to ten percent of patients who are treated for hypertension are considered resistant to treatment. These patients have a major increase in the risk of cardiovascular issues compared with individuals with controlled high blood pressure.
Patients interested in being part of the trial must be between 18 and 80-years-old, have a systolic blood pressure greater than 160 despite taking at least three medications at full tolerated doses, and not have severe kidney failure. Renal denervation is being marketed and clinically used in Europe. It is currently considered an investigative therapy in the United States.
For more information about the SYMPLICITY HTN-3 Trial, please call the clinical trials unit at 312.926.0840.